Speaker Announcement
We are pleased to welcome Dr. Valerie Taly as a featured speaker at the Virtual Liquid Biopsy Symposium.
Dr. Taly is a senior researcher at CNRS, University Paris Cité, France, and Co-Founder, President, and Chief Scientific Officer of METHYS Dx, a biotechnology company dedicated to developing epigenetic-based liquid biopsy tests for cancer detection and monitoring.
Dr. Valerie Taly is an expert in DNA methylation biomarkers and molecular diagnostics. Her research focuses on identifying cancer-specific epigenetic signatures and translating them into highly sensitive, clinically actionable assays. Through her academic work and her leadership at METHYS Dx, she is advancing the use of methylation markers combined with digital PCR technologies to enable precise, real-time monitoring of tumor dynamics, minimal residual disease, and early relapse across multiple cancer types.
In this talk, Dr. Taly will discuss how integrating DNA methylation profiling with digital PCR can significantly enhance the sensitivity and specificity of liquid biopsy. She will highlight how this approach enables robust, quantitative tracking of tumor burden over time, supporting earlier detection of recurrence and more informed treatment decisions in clinical practice.
Join us for an insightful presentation on how epigenetic liquid biopsy and digital technologies are shaping the future of personalized cancer monitoring.
Time: Starts at 12:30 PM, Central European Time
This conference is organized by Impact Research Communications (IRC)
More info: https://liquidbio.ircconferences.net/ | Advances in Liquid Biopsy
